( com.au/>www.biota.com.au . Investor /...)LANI completes Phase I in Japan and to commence Phase I in UK,Health

com.au/">www.biota.com.au.
Investor / Analyst Enquiries Media Enquiries
Biota Holdings Limited Tim Duncan or Nerida Mossop
Peter Cook Hinton & Associates
T: +61 3 9915 3720 T: +61 3 9600 1979
Damian Lismore M: +61 408 441 122
T: +61 3 9915 3721


Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/

Completion of Phase I Trial on the Anti-influenza Drug CS-8958
Tokyo, April 18, 2007 – DAIICHI SANKYO COMPANY, LIMITED announced today that it
has completed a Phase I clinical trial in Japan on the DAIICHI SANKYO-originated antiinfluenza
drug CS-8958 and expects to start Phase II trials this fall.
CS-8958 is a long-acting neuraminidase inhibitor that is expected to show a therapeutic effect
only by one administration and a protective effect by one administration a week. The
compound is under development as an inhalant that will act directly on the pulmonary and
tracheal sites of infection. Non-clinical studies have confirmed its effectiveness against the
H5N1 avian flu virus in addition to its effectiveness against both A and B type non-avian flu
viruses.

CS-8958 was designated as a priority item for face-to-face consultation and advice by the
Pharmaceuticals and Medical Devices Agency (PMDA) in August 2006, which will give it
priority for consultations on clinical trial planning and other issues. DAIICHI SANKYO aims
to file an NDA at end-2009 and is pursuing development in full consultation with the
regul
'"/>




Page: 1 2 3 4
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery